General Forum, page-1689

CardieX is/has moving away from a "Blood Pressure" company deriving differentiation via CBP and PWA to a company specializing in cardiovascular biomarkers ( however they are derived ). It broadens the scope and value of the company enormously. It is why CDX are conducting the longitudinal study to gather evidence around liver function, maternal health and Alzheimer's disease with the intent of FDA submission on unique digital biomarkers on Conneqt Pulse.

Conneqt Pulse, don't think " fancy cuff based blood pressure monitor " but rather " Cardiovascular Biomarker monitor " ... a different value proposition.

Digital biomarkers are precision medicine 2.0

Our healthcare system uses biomarkers to measure our health. Today, these biomarkers are overwhelmingly molecular (blood) in nature. In fact, according to the Centers for Disease Control and Prevention (CDC), 70% of medical decision-making about our health is based on lab test results.³ At my company, BioTrillion, we believe digital biomarkers will one day overtake physical biomarkers in healthcare.

Digital biomarkersoffer a host of advantages to measure our health over molecular biomarkers that are confined to clinical settings, including improved precision, speed, and affordability (better, faster, and cheaper).^4,5

Our current healthcare system still lacks these digital biomarkers, and we believe that healthcare innovators have only begun to scratch the surface of dimensions when it comes to identifying more of them.